A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy

Trial Profile

A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Alendronic acid (Primary) ; Calcium carbonate; Colecalciferol; Tenofovir disoproxil fumarate
  • Indications Bone resorption; Metabolic bone diseases
  • Focus Therapeutic Use
  • Acronyms APART
  • Most Recent Events

    • 19 May 2016 Status changed from not yet recruiting to recruiting.
    • 10 May 2016 Planned initiation date changed from 1 Jan 2016 to 1 May 2016.
    • 02 Dec 2015 Planned initiation date changed from 1 Feb 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top